We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+13.82%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.5B
AUM Growth
+$378M
Cap. Flow
+$252M
Cap. Flow %
1.74%
Top 10 Hldgs %
26.25%
Holding
735
New
61
Increased
261
Reduced
285
Closed
31

Top Buys

Rank Stock Value
1
V icon
Visa
V
+$73.6M
2
GILD icon
Gilead Sciences
GILD
+$57M
3
MSFT icon
Microsoft
MSFT
+$44.1M
4
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$38.6M
5
NU icon
Nu Holdings
NU
+$38M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$112M
2
RY icon
Royal Bank of Canada
RY
+$44.3M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$40.1M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$38.9M
5
MRK icon
Merck
MRK
+$31.7M

Sector Composition

Rank Sector Weight
1 Technology 30.32%
2 Healthcare 28.88%
3 Consumer Discretionary 8.63%
4 Financials 8.52%
5 Industrials 6.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORGN
676
DELISTED
Origin Materials
ORGN
– –
-27,495
Closed -$1.06M
REPL icon
677
Replimune Group
REPL
$426M
– –
-612,193
Closed -$10.5M
RSG icon
678
Republic Services
RSG
$68B
– –
-1,989
Closed -$283K
SE icon
679
Sea Limited
SE
$66.1B
– –
-42,868
Closed -$1.88M
SNAP icon
680
Snap
SNAP
$8.01B
– –
-13,080
Closed –
TENB icon
681
Tenable Holdings
TENB
$3.48B
– –
-501,554
Closed -$22.5M
TREX icon
682
Trex
TREX
$4.4B
– –
-71,396
Closed -$4.4M
VIR icon
683
Vir Biotechnology
VIR
$1.45B
– –
-11,026
Closed –
WLY icon
684
John Wiley & Sons Class A
WLY
$2.84B
– –
-23,407
Closed -$870K
LICY
685
DELISTED
Li-Cycle Holdings Corp.
LICY
– –
-29,250
Closed -$831K
SWAV
686
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
– –
-10,000
Closed -$199K
MRTX
687
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-893,763
Closed -$38.9M
SGEN
688
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-530,228
Closed -$112M
VMW
689
DELISTED
VMware, Inc
VMW
– –
-16,165
Closed -$2.69M
NEWR
690
DELISTED
New Relic, Inc.
NEWR
– –
-3,677
Closed -$315K
ATVI
691
DELISTED
Activision Blizzard
ATVI
– –
-38,141
Closed -$3.56M
24 25 26 27
28

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q4 2023 Portfolio in Review

As of Q4 2023, Candriam SCA held 735 positions worth $14.5B, up 2.7% from $14.1B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Candriam SCA's Q4 2023 filing shows 61 new, 261 increased, 285 reduced and 31 closed positions. Its largest new stake was Nu Holdings: 4,696,438 shares worth $39.1M. The largest sale was Seagen Inc. Common Stock, an estimated $112M.

By sector, the portfolio is most concentrated in Technology at 30% of assets, up from 26% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • Candriam SCA's largest Q4 2023 buy was Nu Holdings: 4,696,438 shares worth $39.1M.
  • Candriam SCA added most to Visa in Q4 2023, an estimated $73.6M increase.
  • Candriam SCA's biggest Q4 2023 reduction was Royal Bank of Canada, cutting an estimated $44.3M.
  • Candriam SCA fully exited Seagen Inc. Common Stock in Q4 2023, selling an estimated $112M.
  • Candriam SCA's ten largest holdings make up 26% of its $14.5B portfolio in Q4 2023.
  • Candriam SCA opened 61 new positions and closed 31 in Q4 2023.
  • Candriam SCA's portfolio value rose 2.7% quarter-over-quarter to $14.5B.

Based on Candriam SCA's 13F filing for Q4 2023, filed 14 Feb 2024.